Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BDTX

BDTX - Black Diamond Therapeutics Inc Stock Price, Fair Value and News

4.84USD-0.14 (-2.81%)Market Closed

Market Summary

BDTX
USD4.84-0.14
Market Closed
-2.81%

BDTX Stock Price

View Fullscreen

BDTX RSI Chart

BDTX Valuation

Market Cap

272.3M

Price/Earnings (Trailing)

-3.41

Price/Sales (Trailing)

141.51

Price/Free Cashflow

-4.01

BDTX Price/Sales (Trailing)

BDTX Profitability

Return on Equity

-76.5%

Return on Assets

-55.99%

Free Cashflow Yield

-24.95%

BDTX Fundamentals

BDTX Revenue

Revenue (TTM)

1.9M

Rev. Growth (Yr)

2.41%

Rev. Growth (Qtr)

1.19%

BDTX Earnings

Earnings (TTM)

-79.8M

Earnings Growth (Yr)

12.69%

Earnings Growth (Qtr)

6.1%

Breaking Down BDTX Revenue

Last 7 days

-18.9%

Last 30 days

-4.0%

Last 90 days

-15.7%

Trailing 12 Months

160.2%

How does BDTX drawdown profile look like?

BDTX Financial Health

Current Ratio

7.05

BDTX Investor Care

Shares Dilution (1Y)

54.06%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20232.3M001.9M
20222.7M02.3M2.2M
20214.4M4.5M4.1M3.5M
20201.2M2.1M3.2M4.0M
2019000461.0K

Tracking the Latest Insider Buys and Sells of Black Diamond Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 21, 2024
raman prakash
acquired
11,459
4.98
2,301
-
Jun 21, 2024
behbahani ali
acquired
14,377
4.98
2,887
-
Jun 21, 2024
campbell shannon
acquired
10,014
4.98
2,011
-
Mar 15, 2024
dixon wendy l
acquired
14,768
4.54
3,253
-
Mar 15, 2024
behbahani ali
acquired
14,373
4.54
3,166
-
Dec 15, 2023
dixon wendy l
acquired
11,037
2.73
4,043
-
Dec 15, 2023
behbahani ali
acquired
12,162
2.73
4,455
-
Oct 17, 2023
biotech growth n v
bought
934,080
2.3352
400,000
-
Sep 15, 2023
velleca mark a.
acquired
18,748
3.6
5,208
president & ceo
Sep 15, 2023
behbahani ali
acquired
11,876
3.6
3,299
-

1–10 of 50

Which funds bought or sold BDTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-1,561,160
-
-%
May 17, 2024
Artal Group S.A.
reduced
-48.86
-445,159
5,305,840
0.14%
May 16, 2024
Beacon Capital Management, LLC
unchanged
-
34,353
79,168
0.02%
May 16, 2024
JANE STREET GROUP, LLC
added
353
1,115,000
1,270,310
-%
May 15, 2024
Driehaus Capital Management LLC
reduced
-13.07
1,113,440
3,071,920
0.03%
May 15, 2024
Federation des caisses Desjardins du Quebec
new
-
2,840
2,840
-%
May 15, 2024
SHERBROOKE PARK ADVISERS LLC
new
-
55,324
55,324
0.01%
May 15, 2024
BARCLAYS PLC
unchanged
-
378,000
848,000
-%
May 15, 2024
T. Rowe Price Investment Management, Inc.
added
71.22
23,060,000
34,098,000
0.02%
May 15, 2024
Blue Owl Capital Holdings LP
unchanged
-
1,570,700
3,523,650
0.70%

1–10 of 48

Are Funds Buying or Selling BDTX?

Are funds buying BDTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BDTX
No. of Funds

Unveiling Black Diamond Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 13, 2024
new enterprise associates 16, l.p.
7.9%
4,448,757
SC 13D/A
May 09, 2024
ra capital management, l.p.
4.95%
2,788,028
SC 13D/A
Mar 11, 2024
t. rowe price investment management, inc.
12.9%
6,675,756
SC 13G/A
Feb 14, 2024
t. rowe price investment management, inc.
7.6%
3,927,879
SC 13G
Feb 13, 2024
bb biotech ag
16.5%
8,517,839
SC 13G/A
Nov 09, 2023
versant venture capital vi, l.p.
7.7%
3,947,941
SC 13D/A
Feb 14, 2023
bb biotech ag
14.8%
5,377,839
SC 13G/A
Jul 08, 2022
blackrock inc.
3.5%
1,272,112
SC 13G
Apr 14, 2022
bb biotech ag
11.0%
3,988,402
SC 13G/A
Feb 11, 2022
bb biotech ag
9.5%
3,440,000
SC 13G/A

Recent SEC filings of Black Diamond Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 21, 2024
144
Notice of Insider Sale Intent
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 20, 2024
144
Notice of Insider Sale Intent
Jun 20, 2024
144
Notice of Insider Sale Intent
Jun 18, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 13, 2024
144
Notice of Insider Sale Intent
Jun 12, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Black Diamond Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Black Diamond Therapeutics Inc News

Latest updates
MarketBeat15 Jun 202403:32 pm
Clinical Trials Arena6 months ago
Pharmaceutical Technology11 months ago

Black Diamond Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q12022Q42022Q32022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue1.2%6376306226775624065887769481,1521,2541,1628817444401.009.0011.00
Operating Expenses-2.9%20,24620,85521,56121,85222,12425,67926,08035,36434,71530,71323,18318,48015,02812,87910,3448,1486,9993,841
  S&GA Expenses20.4%6,7015,5666,8087,2436,2777,8936,4167,7387,9967,8935,4275,5514,8585,5252,8842,5141,353828
  R&D Expenses-11.4%13,54515,28914,75314,60915,84717,78619,66427,62626,71922,82017,75612,92910,1707,3547,4605,6345,6463,013
Interest Expenses-------------1.00-----
Net Income6.1%-18,225-19,408-20,875-21,078-21,654-25,507-25,867-35,077-34,351-30,301-22,626-17,912-14,571-12,145-9,875-9,268-12,287-3,828
Net Income Margin3.2%-41.47*-42.85*-38.17*-40.83*-41.15*-44.45*-36.26*-29.63*-23.29*---------
Free Cashflow-51.9%-21,199-13,956-20,031-21,939-16,468-28,607-24,379-27,971-26,013---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets-10.1%14315917212013615618019921924827428831333034634936315852.00
  Current Assets-11.4%11913414793.0010812815116918821624227129732033620836215652.00
    Cash Equivalents-54.8%25.0056.0058.0042.0039.0035.0054.0056.0054.0067.0047.0037.0014.0036.0056.0064.0035715552.00
  Net PPE-5.0%2.002.002.002.002.003.003.003.003.003.003.002.001.000.000.000.000.000.000.00
Liabilities-8.6%38.0042.0038.0038.0037.0041.0047.0046.0047.0052.0055.0037.0033.0022.0019.006.008.005.007.00
  Current Liabilities-14.2%17.0020.0015.0014.0013.0015.0021.0020.0019.0024.0026.0023.0019.0014.0011.006.007.005.003.00
Shareholder's Equity-10.6%10411713482.0098.00116133152173196219251281308327343355--
  Retained Earnings-4.4%-435-417-398-375-355-334-313-292-269-243-217-182-148-118-95.60-77.69-63.11-50.97-15.71
  Additional Paid-In Capital1.1%5405345334584554534504474444404374344294254224204184.000.00
Shares Outstanding1.7%53.0052.0052.0037.0036.0036.0036.0036.0036.0036.0036.0036.00-------
Float----115---55.00---340---1,010---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-51.9%-21,199-13,956-18,362-14,368-20,031-21,939-16,476-18,067-28,600-24,046-26,482-25,165-24,455-15,774-11,486-13,567-11,319-7,486-5,310-5,000-6,878
  Share Based Compensation11.5%1,7131,5362,7512,6462,6712,9062,6643,2523,3753,3763,0094,5583,0942,4701,9991,4191,8772,51085019291.00
Cashflow From Investing-212.1%-13,73412,249-37,88417,17524,8062,32214,50719,80816,72943,24235,69748,2003,474-6,6484,597-279,640--2.00-11.002.00-10.00
Cashflow From Financing9078.3%4,130-46.0071,927-51.00-28.0052.00-153-64.00184481830270-213,84483,49544,331-70.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BDTX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 13,545$ 14,753
General and administrative6,7016,808
Total operating expenses20,24621,561
Loss from operations(20,246)(21,561)
Other income (expense):  
Interest income637622
Other income (expense)1,38464
Total other income (expense), net2,021686
Net loss$ (18,225)$ (20,875)
Net loss per share, basic (in dollars per share)$ (0.35)$ (0.57)
Net loss per share, diluted (in dollars per share)$ (0.35)$ (0.57)
Weighted average common shares outstanding, basic (in shares)51,808,84936,483,878
Weighted average common shares outstanding, diluted (in shares)51,808,84936,483,878
Comprehensive loss:  
Net loss$ (18,225)$ (20,875)
Other comprehensive income (loss):  
Unrealized gain (loss) on investments, net(68)648
Comprehensive loss$ (18,293)$ (20,227)

BDTX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 25,422$ 56,221
Investments89,77775,179
Prepaid expenses and other current assets3,6072,634
Total current assets118,806134,034
Property and equipment, net1,6441,730
Restricted cash819823
Right-of-use assets21,25221,980
Total assets142,521158,567
Current liabilities:  
Accounts payable1,1762,324
Accrued expenses and other current liabilities15,67817,322
Total current liabilities16,85419,646
Non-current operating lease liabilities21,36122,185
Total liabilities38,21541,831
Commitments and contingencies (Note 11)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 202300
Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 202377
Additional paid-in capital540,050534,187
Accumulated other comprehensive loss(95)(27)
Accumulated deficit(435,656)(417,431)
Total stockholders' equity104,306116,736
Total liabilities and stockholders' equity$ 142,521$ 158,567
BDTX
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEblackdiamondtherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES65

Black Diamond Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Black Diamond Therapeutics Inc? What does BDTX stand for in stocks?

BDTX is the stock ticker symbol of Black Diamond Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Black Diamond Therapeutics Inc (BDTX)?

As of Fri Jun 21 2024, market cap of Black Diamond Therapeutics Inc is 272.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDTX stock?

You can check BDTX's fair value in chart for subscribers.

What is the fair value of BDTX stock?

You can check BDTX's fair value in chart for subscribers. The fair value of Black Diamond Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Black Diamond Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BDTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Black Diamond Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BDTX is over valued or under valued. Whether Black Diamond Therapeutics Inc is cheap or expensive depends on the assumptions which impact Black Diamond Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDTX.

What is Black Diamond Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, BDTX's PE ratio (Price to Earnings) is -3.41 and Price to Sales (PS) ratio is 141.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDTX PE ratio will change depending on the future growth rate expectations of investors.